Diagnostic Ionizing Radiation Exposure in a Population-Based Cohort of Children with Inflammatory Bowel Disease
|
|
- Frederick Quinn
- 5 years ago
- Views:
Transcription
1 Diagnostic Ionizing Radiation Exposure in a Population-Based Cohort of Children with Inflammatory Bowel Disease Lena B. Palmer MD, Carol Q. Porter, Michael D. Kappelman MD MPH No relevant financial disclosures
2 Disclosures: I do not have any relevant financial relationships with ihany commercial ilinterests
3 Background Ionizing radiation may increase the risk of malignancy Risk to children is higher than to adults Excess risk of cancer death attributed to CT prior to age 15 estimated at 1:2000 Diagnostic radiation has become an important component of evaluation and management of inflammatory bowel disease (IBD) Little is known about utilization of diagnostic radiation in children with IBD Brenner, Pediatric Radiology 2002; 32: ; Newnham et al. Aliment Pharmacol Ther. 2007;26(7): Desmond et al. Gut Peloquin et al. Am J Gastroenterol. 2008;103(8):
4 Aims 1) To describe the utilization of diagnostic ionizing radiation in a population-based cohort of pediatric patients (age 18) with ulcerative colitis (UC) or Crohn s disease (CD) 2) To determine patient characteristics associated with moderate/high-dosedose radiation exposure
5 Methods Study Design Cross-sectional analysis of health insurance claims, Subjects 3 claims with primary diagnosis of UC or CD or 1 claim & 1 Rx for an IBD-specific medication* Continuously enrolled over 24 month observation period Source of Data PharMetrics Patient t Centric Database (IMS Health, Watertown, MA) 87 health plans, 33 states *Kappelman et al. Clin Gastro Hep. 2007;5(12):
6 Outcome Description All occurrences of 23 diagnostic studies identified via CPT codes X-rays of chest, abdomen, pelvis, bone mineral density, IVP Upper GI series, small bowel series, barium enema, fistulogram, ERCP, cholangiogram, enteroclysis, CT enterography, CT & CTA of head, neck, extremities, chest, coronaries, abdomen, pelvis Studies classified by level of dose Low dose (X-ray); average 0.06 msv Medium dose (Fluoroscopy); average 4.5 msv High dose (CT); average 5.9 msv
7 Imaging Utilization Comparison Age Gender Geographical region (East, South, Midwest, West) IBD medication use (oral/rectal salicylates, infliximab, adalimumab, methotrexate, 6-MP/ azathioprine, and oral steroids) Requirement for hospitalization or inpatient GI surgery Statistical Analysis: Pearson s Chi-Square and Wilcoxon Rank-Sum
8 Regression Analysis Characteristics associated with moderate/ high dose imaging 1 high dose study or 3 medium dose studies Multivariable logistic regression Separate models for UC and CD Some medications not commonly used in UC at the time of the study were excluded from regression modeling due to sparse observations (infliximab & adalimumab)
9 Sample Characteristics
10 Moderate/High Dose Imaging by Disease Type % Receipt Mod/High Dose Imaging Ulcerative Colitis Crohn's Disease
11 Distribution of Study Type, Crohn s Disease 100% 80% 60% 40% 20% 0% Number of Studies Effective Dose CT Fluoroscopy X-ray
12 Factors associated with Moderate/High Dose Imaging
13 Factors associated with Moderate/High Dose Imaging
14 Immunomodulators & Moderate/High Dose Imaging *Crohn s subjects only
15 Summary 33% of Crohn s Disease & 23% of UC exposed to moderate/ high dose imaging Surgery, hospitalization, & oral steroid use are positively associated Immunomodulator use is inversely associated in Immunomodulator use is inversely associated in Crohn s disease subjects unexposed to steroids
16 Potential Limitations Cross-sectional design Administrative data lacks clinical detail Misclassification bias Unable to sub-classify by disease phenotype, extent, severity & time from diagnosisi
17 Strengths Large, population-based pediatric cohort Able to examine UC and CD independently Complete capture of all imaging g studies
18 Conclusions Over 2 years, a substantial proportion of children were exposed to ionizing radiation A lifetime of diagnostic testing will magnify the risk Dose-reduction strategies or alternative Dose reduction strategies or alternative procedures are needed to avoid unnecessary risk of malignancy
19 Acknowledgements Special thanks to Hans Herfarth, MD & Lynn Fordham, MD for their guidance in completion of this work This work was supported by T32 NIH training grant number 5-T32 DK and CGIBD grant number P30 DK
20
21 Risk from one Abdominal CT 5-15 yr old 1 in excess risk Brenner, Pediatric Radiology 2002; 32:
22 Effective Dose GI Radiology
23 Total Number of Studies by Study Type #Studies Ulcerative Colitis Crohn's Disease CT Fluoroscopy X-ray
24 Total Effective Dose by Study Type Eff. Dose 4000 (msv) Ulcerative Colitis Crohn's Disease CT Fluoroscopy X-Ray
25
26 Lifetime Attributable Risk Brenner, Pediatric Radiology 2002; 32:
27 Quantifying exposure to diagnostic medical radiation in patients with IBD: are we contributing to malignancy? Newnham et al, Alim Pharm Ther 2007: 26 ( ) Single, tertiary IBD referral center (Australia) 100 consecutive pt, 62 CD/48 UC Mean Age 39 (16-84) UK radiation tables used to assign ED*; 50 msv considered high risk Results: Med ED 10 msv (0 277); Med Annual Rate = 5.4 msv 11 % received 50 msv 31 % received no abdominal exposure CD & pt undergoing surgery had increased odds of exposure *ED = Effective Dose OR for UC 0.33 (95%CI ), OR 3.01 (95%CI )
28 Crohn's disease: factors associated with exposure to high levels of diagnostic radiation Desmond et al, Gut 2008: (online) April 29 Single, tertiary referral center (Ireland) 325 pt, Mean age 32 (8 78) July 1992-June 2007; mean f/u 6.7 yrs UK radiation tables used to assign ED; 75 msv considered high risk Results: CT: 16% of exposure, 77% of total ED Mean ED 36.1 msv; Mean annual rate: 8.1 msv 15.5% received >75 msv 24.9% received no exposure
29
30 Mean no. studies per pt Mean CED per pt
31 Diagnostic Ionizing Radiation Exposure in a Population-Based Cohort of Patients with IBD Peloquin et al, Am J Gastro 2008;103:1 8 Population based (Olmsted Co) 215 pt, 103 CD/ 112 UC; Mean age at dz 38/ 39 Jan Dec 2001; mean f/u 9 yr ED calculated using institution parameters, individual patient data & published estimates Results: CT: 12% of exposure, 51% / 40% of ED for CD/ UC Med ED= 26.6 msv (0 279) & 10.5 msv (0 251) Med Annual Rate = 3.1 msv / 1.2 msv CD received 2.46 times ED than UC (P = 0.001)
32 Summary Diagnostic medical radiation may increase risk of malignancy Children are more vulnerable to radiation than adults Adults with IBD undergo multiple imaging studies Some exposed to high levels of radiation Little is known about diagnostic medical radiation exposure in children with IBD
Position of Biologics in IBD Circa 2006: Top Down vs. Step Up Therapy
Position of Biologics in IBD Circa 2006: Top Down vs. Step Up Therapy Stephen B. Hanauer, MD University of Chicago Potential Conflicts: Centocor/Schering, Abbott, UCB, Elan, Berlex, PDL Goals of Treatment
More informationIBD Understanding Your Medications. Thomas V. Aguirre, MD Santa Barbara GI Consultants
IBD Understanding Your Medications Thomas V. Aguirre, MD Santa Barbara GI Consultants IBD Understanding Your Medications (& Your Doctor) Thomas V. Aguirre, MD Santa Barbara GI Consultants Disclosure I
More informationRadiation Exposure From Diagnostic Imaging Among Patients With Gastrointestinal Disorders
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2012;10:259 265 Radiation Exposure From Diagnostic Imaging Among Patients With Gastrointestinal Disorders ALAN N. DESMOND, SEBASTIAN MCWILLIAMS, MICHAEL M. MAHER,
More informationTreatment of Pediatric IBD: What is Different?
Treatment of Pediatric IBD: What is Different? January 13, 2017 Michael Kappelman MD, MPH University of North Carolina at Chapel Hill Overview Is Pediatric IBD the same disease? Treatment considerations
More informationIn 2005, US health care spending increased by 6.9% to
GASTROENTEROLOGY 2008;135:1907 1913 Direct Health Care Costs of Crohn s Disease and Ulcerative Colitis in US Children and Adults MICHAEL D. KAPPELMAN,* SHERYL L. RIFAS SHIMAN, CAROL Q. PORTER, DANIEL A.
More informationRadiation Exposure from Abdominal Imaging Studies in Patients with Intestinal Behçet Disease
Gut and Liver, Vol. 8, No. 4, July 2014, pp. 380-387 ORiginal Article Radiation Exposure from Abdominal Imaging Studies in Patients with Intestinal Behçet Disease Yoon Suk Jung*,, Dong Il Park, Chang Mo
More informationAbdominal MRI in the Emergency Setting
Abdominal MRI in the Emergency Setting Ivan Pedrosa, MD, FSCBTMR UT Southwestern Medical Center. Dallas, TX MRI Use in Tertiary Care ED (01-05) 391% increase in ED MRI (1,900 exams) 38.9% total MRI increase
More informationDENOMINATOR: All patients aged 18 and older with a diagnosis of inflammatory bowel disease
Measure #270: Inflammatory Bowel Disease (IBD): Preventive Care: Corticosteroid Sparing Therapy National Quality Strategy Domain: Effective Clinical Care 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY
More informationRadiation Exposure in Gastroenterology
Radiation Exposure in Gastroenterology Immanuel K. Ho, M.D., FACG, FASGE, AGAF Clinical Professor of Medicine Temple University School of Medicine Crozer-Chester Medical Center, USA Ionizing Radiation
More informationOne in five Americans develop skin cancer, which accounts. Increased Risk for Non-Melanoma Skin Cancer in Patients With Inflammatory Bowel Disease
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2010;8:268 274 Increased Risk for Non-Melanoma Skin Cancer in Patients With Inflammatory Bowel Disease MILLIE D. LONG,* HANS H. HERFARTH,* CLARE A. PIPKIN, CAROL
More informationEfficacy and Safety of Treatment for Pediatric IBD
Efficacy and Safety of Treatment for Pediatric IBD Andrew B. Grossman MD Co-Director, Center for Pediatric Inflammatory Bowel Disease Associate Professor of Clinical Pediatrics Division of Gastroenterology,
More informationSeptember 12, 2015 Millie D. Long MD, MPH, FACG
Update on Biologic Therapy in 2015 September 12, 2015 Millie D. Long MD, MPH, FACG Assistant Professor of Medicine Inflammatory Bowel Disease Center University of North Carolina-Chapel Hill Outline Crohn
More informationOptimizing the effectiveness of anti-tnf therapy in paediatric IBD
Optimizing the effectiveness of anti-tnf therapy in paediatric IBD Anne Griffiths MD, FRCPC Co-Lead, Inflammatory Bowel Disease Center Northbridge Chair in IBD Hospital for Sick Children, Professor of
More informationDiagnostic imaging and radiation exposure in inflammatory bowel disease
Submit a Manuscript: http://www.wjgnet.com/esps/ Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx DOI: 10.3748/wjg.v22.i7.2165 World J Gastroenterol 2016 February 21; 22(7): 2165-2178 ISSN 1007-9327
More informationEpidemiology and Treatment of Colonic Angiodysplasia; a Population-Based Study. Naomi G. Diggs, MD Lisa L. Strate, MD MPH March 2, 2010
Epidemiology and Treatment of Colonic Angiodysplasia; a Population-Based Study. Naomi G. Diggs, MD Lisa L. Strate, MD MPH March 2, 2010 Background Angiodysplasia is an important cause of occult and acute
More informationAzathioprine for Induction and Maintenance of Remission in Crohn s Disease
Azathioprine for Induction and Maintenance of Remission in Crohn s Disease William J. Sandborn, MD Chief, Division of Gastroenterology Director, UCSD IBD Center Objectives Azathioprine as induction and
More informationMedical Therapy for Pediatric IBD: Efficacy and Safety
Medical Therapy for Pediatric IBD: Efficacy and Safety Betsy Maxwell, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition Pediatric IBD: Defining Remission
More informationImproving outcome of Inflammatory Bowel Disease in children
Improving outcome of Inflammatory Bowel Disease in children Dinesh Pashankar, MD Pediatric Gastroenterologist Director- Pediatric IBD program Yale University School of Medicine Pediatric Gastroenterology
More informationPredictors of DEXA Use and Guideline Performance for the Detection of Low Bone Mineral Density in Inflammatory Bowel Disease
Predictors of DEXA Use and Guideline Performance for the Detection of Low Bone Mineral Density in Inflammatory Bowel Disease Jason Etzel Resident Research Forum Seattle VAMC 6/13/08 Background Increased
More informationChoosing and Positioning Biologic Therapy for Crohn s Disease: (Still) Looking for the Crystal Ball
Choosing and Positioning Biologic Therapy for Crohn s Disease: (Still) Looking for the Crystal Ball Siddharth Singh, MD, MS Assistant Professor of Medicine Division of Gastroenterology Division of Biomedical
More informationEpidemiology of IBD in Pediatric Patients in the US: Data from the ImproveCareNow Registry
Epidemiology of IBD in Pediatric Patients in the US: Data from the ImproveCareNow Registry Michael D. Kappelman, MD Professor of Pediatrics and Epidemiology University of North Carolina, Chapel Hill Richard
More informationIBD and Cancer: Myths and Facts
IBD and Cancer: Myths and Facts Thomas A. Ullman, MD Medical Director, Faculty Prac>ce Department of Medicine Icahn School of Medicine at Mount Sinai New York, USA Risk of Colorectal Cancer in UC Eaden
More informationWhat is Crohn's disease?
What is Crohn's disease? Crohn's disease is a chronic inflammatory disorder that causes inflammation of the digestive tract. It can affect any area of the GI tract, from the mouth to the anus, but it most
More informationPrimary & Secondary Care Inflammatory Bowel Disease Pathway February 2018
South East London Area Prescribing Committee: Primary & Secondary Care Inflammatory Bowel Disease Pathway February 2018 Developed by: South East London IBD Pathway Development Group Approved: February
More informationEstimating Risks from CT Scans - in the Context of CT Scan Benefits
Estimating Risks from CT Scans - in the Context of CT Scan Benefits David J. Brenner Center for Radiological Research Columbia University Medical Center djb3@cumc.columbia.edu There is no question that
More informationchildren Crohn s disease in MR enterography for GI Complications Microscopy Characterization Primary sclerosing cholangitis Anorectal fistulae
MR enterography for Crohn s disease in children BOAZ KARMAZYN, MD PEDIATRIC RADIOLOGY ASSOCIATE PROFESSOR Characterization Crohn disease Idiopathic chronic transmural IBD Increasing incidence Age 7/100,000
More informationCRC and Dysplasia in IBD: Objectives of Talk. Colorectal Cancer and Dysplasia in IBD: A Case-Based Approach. Page 1
Colorectal Cancer and in IBD: A Case-Based Approach Fernando Velayos MD MPH Associate Director of Translational Research University of California, San Francisco Center for Crohn s s and Colitis CRC and
More informationInitiation of Maintenance Treatment in Moderate to Severe New Onset Crohn s Disease
Initiation of Maintenance Treatment in Moderate to Severe New Onset Crohn s Disease The Case for Starting with Anti-TNFα Agents Maria Oliva-Hemker, M.D. Chief, Division of Pediatric Gastroenterology &
More informationEPIDEMIOLOGY OF INFLAMMATORY BOWEL DISEASE IN PEDIATRIC PATIENTS
EPIDEMIOLOGY OF INFLAMMATORY BOWEL DISEASE IN PEDIATRIC PATIENTS ERIC BENCHIMOL, MD, PhD, FRCPC Associate Professor of Pediatrics and Epidemiology, University of Ottawa Pediatric Gastroenterologist, CHEO
More informationEast west gradient in the incidence of inflammatory bowel disease in Europe: the ECCO-EpiCom inception cohort
East west gradient in the incidence of inflammatory bowel disease in Europe: the ECCO-EpiCom inception cohort diseasespictures.com Balazs Radnai and Martin Eigler Statistik II. Course 27.01.2014. Introduction
More informationAustralian Per Caput Doses from Diagnostic Imaging and Nuclear Medicine
Australian Per Caput Doses from Diagnostic Imaging and Nuclear Medicine A.J.M Hayton, P.N Johnston, J Baldas, P.A Marks, K Edmonds, A.B Wallace Australian Radiation Protection and Nuclear Safety Agency,
More information-2002: Rectal blood loss, UC? (no definite diagnosis) rectal mesalazine. -June 2008: Recurrence of rectal blood loss and urgency
SD, male 40 yrs. old. (680718M467.) -2002: Rectal blood loss, UC? (no definite diagnosis) rectal mesalazine -June 2008: Recurrence of rectal blood loss and urgency Total colonoscopy: ulcerative rectitis,
More informationPerianal and Fistulizing Crohn s Disease: Tough Management Decisions. Jean-Paul Achkar, M.D. Kenneth Rainin Chair for IBD Research Cleveland Clinic
Perianal and Fistulizing Crohn s Disease: Tough Management Decisions Jean-Paul Achkar, M.D. Kenneth Rainin Chair for IBD Research Cleveland Clinic Talk Overview Background Assessment and Classification
More informationUse of extrapolation in small clinical trials:
Use of extrapolation in small clinical trials: Infliximab for pediatric ulcerative colitis Jessica J. Lee, MD, MMSc Medical Officer Division of Gastroenterology and Inborn Errors Products CDER/ FDA 1 Learning
More informationFistulizing Crohn s Disease: The Aggressive Approach
Fistulizing Crohn s Disease: The Aggressive Approach Bruce E. Sands, MD, MS MGH Crohn s and Colitis Center and Gastrointestinal Unit Massachusetts General Hospital Boston, USA Case Presentation: Summary
More informationTreatment of ulcerative colitis with adalimumab or infliximab: long-term follow-up of a single-centre cohort
Alimentary Pharmacology and Therapeutics Treatment of ulcerative colitis with adalimumab or infliximab: long-term follow-up of a single-centre cohort N. Gies, K. I. Kroeker, K. Wong & R. N. Fedorak Division
More informationPregnancy in IBD CDDW 2014
Pregnancy in IBD CDDW 2014 Brian Bressler MD, MS, FRCPC Director, Advanced IBD Training Program Clinical Assistant Professor of Medicine Division of Gastroenterology University of British Columbia Bressler
More informationRisk = probability x consequence
Explaining Risks of IBD Therapy to Parents and Patients December 4, 2009 CCFA Advances in IBD Hollywood, FL Corey A. Siegel Assistant Professor of Medicine, Dartmouth Medical School Director, Dartmouth-Hitchcock
More informationEarly in Life. Noboru Takamura, M.D., Ph.D.
Health Risks of Radiation Exposure Early in Life Noboru Takamura, M.D., Ph.D. Diagnostic Radiologic Procedures In recent years, the largest source of general population exposure to radiation has shifted
More informationAccepted Manuscript. Does eradication of Helicobacter pylori cause inflammatory bowel disease? Johan Burisch, Tine Jess
Accepted Manuscript Does eradication of Helicobacter pylori cause inflammatory bowel disease? Johan Burisch, Tine Jess PII: S1542-3565(19)30153-3 DOI: https://doi.org/10.1016/j.cgh.2019.02.013 Reference:
More informationOptimizing Immunomodulators and
Optimizing Immunomodulators and Biologics i in Inflammatory Bowel Disease Sunanda Kane, MD, MSPH, FACG Professor of Medicine Division of Gastroenterology and Hepatology Mayo Clinic Rochester, Minnesota,
More informationIonizing radiation in patients with Crohn s disease. Estimation and associated factors
1130-0108/2012/104/9/452-457 REVISTA ESPAÑOLA DE ENFERMEDADES DIGESTIVAS Copyright 2012 ARÁN EDICIONES, S. L. REV ESP ENFERM DIG (Madrid) Vol. 104. N. 9, pp. 452-457, 2012 ORIGINAL PAPERS Ionizing radiation
More informationThe Best of IBD at UEGW (Crohn s)
The Best of IBD at UEGW (Crohn s) Iyad Issa MD Head of Gastroenterology, Rafik Hariri Univ Hosp Adjunct Faculty, School of Medicine, Leb Univ Founding Faculty, School Of Medicine, Leb Am Univ 1 The Best
More informationMedical therapies and IBD
Medical therapies and IBD Although there is no cure for IBD, there are many treatment options available. There is no standard treatment for IBD that is effective in all situations or for all patients,
More informationSystematic reviews and meta-analyses of observational studies (MOOSE): Checklist.
Systematic reviews and meta-analyses of observational studies (MOOSE): Checklist. MOOSE Checklist Infliximab reduces hospitalizations and surgery interventions in patients with inflammatory bowel disease:
More informationPersonalized Medicine in IBD: Where Are We in 2013
Personalized Medicine in IBD: Where Are We in 2013 David A. Schwartz, MD Director, Inflammatory Bowel Disease Center Associate Professor of Medicine Vanderbilt University Medical Center What is Personalized
More informationEfficacy and Safety of Treatment for Pediatric IBD
Efficacy and Safety of Treatment for Pediatric IBD Andrew B. Grossman MD Co-Director, Center for Pediatric Inflammatory Bowel Disease Assistant Professor of Clinical Pediatrics Division of Gastroenterology,
More informationPatti Edwards, Senior Radiographer, West Herts Hospitals, UK. February Radiation Safety
Patti Edwards, Senior Radiographer, West Herts Hospitals, UK. February 2008. Radiation Safety Sub -headings Background Radiation Effects of Radiation Safe Levels Effective Doses ALARA Principle Radiation
More informationRecent Advances in the Management of Refractory IBD
Recent Advances in the Management of Refractory IBD Raina Shivashankar, M.D. Assistant Professor of Medicine Division of Gastroenterology and Hepatology Thomas Jefferson University Philadelphia, PA Outline
More informationRESEARCH ARTICLE. Radiation Exposure in Patients with Inflammatory Bowel Disease: a Fourteen-Year Review at a Tertiary Care Centre in Malaysia
DOI:10.22034/APJCP.2017.18.4.933 RESEARCH ARTICLE Radiation Exposure in Patients with Inflammatory Bowel Disease: a Fourteen-Year Review at a Tertiary Care Centre in Malaysia Jeevinesh Naidu 1 *, Zhiqin
More informationZhao Y Y et al. Ann Intern Med 2012;156:
Zhao Y Y et al. Ann Intern Med 2012;156:560-569 Introduction Fibrates are commonly prescribed to treat dyslipidemia An increase in serum creatinine level after use has been observed in randomized, placebocontrolled
More informationNEW CONCEPTS IN CROHN S DISEASE GLENDON BURRESS, MD PEDIATRIC GASTROENTEROLOGY ROCKFORD, IL
NEW CONCEPTS IN CROHN S DISEASE GLENDON BURRESS, MD PEDIATRIC GASTROENTEROLOGY ROCKFORD, IL CROHN S DISEASE Chronic disease of uncertain etiology Etiology- genetic, environmental, and infectious Transmural
More informationHow to Optimize Induction and Maintenance Responses: Definitions and Dosing Advances in Inflammatory Bowel Disease December 6, 2009
How to Optimize Induction and Maintenance Responses: Definitions and Dosing 2009 Advances in Inflammatory Bowel Disease December 6, 2009 Fernando Velayos MD MPH University of California, San Francisco
More informationIonizing Radiation Exposure of the Population of the United States. David A. Schauer Executive Director
Ionizing Radiation Exposure of the Population of the United States David A. Schauer Executive Director Key Dates in NCRP s s History 1929: U.S. Advisory Committee on X-ray and Radium Protection 1946: U.S.
More informationPredicting the natural history of IBD. Séverine Vermeire, MD, PhD Department of Gastroenterology University Hospital Leuven Belgium
Predicting the natural history of IBD Séverine Vermeire, MD, PhD Department of Gastroenterology University Hospital Leuven Belgium Patient 1 Patient 2 Age 22 Frequent cramps and diarrhea for 6 months Weight
More information2013 Charleston Swallowing Conference
Providing Quality Affordable Continuing Education and Treatment Materials for over 30 years. 2013 Charleston Swallowing Conference Working Breakfast 7:30 8:00 am Saturday, Oct. 12, 2013 CE Seminars On-line
More informationCan We Predict the Natural History of Ulcerative Colitis? Edward V Loftus, Jr, MD Professor of Medicine Mayo Clinic Rochester, Minnesota, USA
Can We Predict the Natural History of Ulcerative Colitis? Edward V Loftus, Jr, MD Professor of Medicine Mayo Clinic Rochester, Minnesota, USA Endpoints Overview Hospitalization Surgery Colorectal cancer
More informationPEDIATRIC INFLAMMATORY BOWEL DISEASE
PEDIATRIC INFLAMMATORY BOWEL DISEASE Alexis Rodriguez, MD Pediatric Gastroenterology Advocate Children s Hospital Disclosers Abbott Nutrition - Speaker Inflammatory Bowel Disease Chronic inflammatory disease
More informationPage 1. Is the Risk This High? Dysplasia in the IBD Patient. Dysplasia in the Non IBD Patient. Increased Risk of CRC in Ulcerative Colitis
Screening for Colorectal Neoplasia in Inflammatory Bowel Disease Francis A. Farraye MD, MSc Clinical Director, Section of Gastroenterology Co-Director, Center for Digestive Disorders Boston Medical Center
More informationPersonalized Medicine in IBD
Personalized Medicine in IBD Anita Afzali MD, MPH Assistant Professor of Medicine Director, Inflammatory Bowel Diseases Program University of Washington Harborview Medical Center CCFA April 2 nd, 2016
More informationAnti-TNF and cyclosporine are identical choices for severe ulcerative colitis refractory to steroid therapy CON Peter Laszlo LAKATOS Semmelweis
Anti-TNF and cyclosporine are identical choices for severe ulcerative colitis refractory to steroid therapy CON Peter Laszlo LAKATOS Semmelweis University, 1st Department of Medicine Budapest June 13-15,
More informationNIH Public Access Author Manuscript Am J Gastroenterol. Author manuscript; available in PMC 2011 September 1.
NIH Public Access Author Manuscript Published in final edited form as: Am J Gastroenterol. 2010 September ; 105(9): 1986 1993. doi:10.1038/ajg.2010.124. Isotretinoin Use and the Risk of Inflammatory Bowel
More informationA Bad Outcome. Drugs don t work in patients who don t take them. Does Compliance Really Matter? Why Should I Care about This?
Does Compliance Really Matter? Sunanda Kane MD, MSPH, FACG, FACP, AGAF Professor of Medicine Mayo Clinic Drugs don t work in patients who don t take them C. Everett Koop A Bad Outcome Why Should I Care
More informationImmunogenicity of Biologic Agents and How to Prevent Sensitization
Immunogenicity of Biologic Agents and How to Prevent Sensitization William J. Sandborn, MD Professor and Chief, Division of Gastroenterology Director, UCSD IBD Center La Jolla, California, USA Learning
More informationMEDICAL POLICY. Proprietary Information of YourCare Health Plan
MEDICAL POLICY Clinical criteria used to make utilization review decisions are based on credible scientific evidence published in peer reviewed medical literature generally recognized by the medical community.
More informationIBD 101. Ronen Stein, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition
IBD 101 Ronen Stein, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition Objectives Identify factors involved in the development of inflammatory bowel
More informationTo help protect your privacy, PowerPoint prevented this external picture from being automatically downloaded. To download and display this picture,
To help protect your privacy, PowerPoint prevented this external picture from being automatically downloaded. To download and display this picture, click Options in the Message Bar, and then click Enable
More informationDefinitions. Clinical remission: Resolution of symptoms (stool frequency 3/day, no bleeding and no urgency)
CROHN S DISEASE Definitions Clinical remission: Resolution of symptoms (stool frequency 3/day, no bleeding and no urgency) Recurrence: The reappearance of lesions after surgical resection Endoscopic remission:
More informationDeterminants of Topical 5-Aminosalicylic Acid Use in Veterans with Ulcerative Colitis
Research Article imedpub Journals http://www.imedpub.com/ Abstract Determinants of Topical 5-Aminosalicylic Acid Use in Veterans with Ulcerative Colitis Aims: The aim of our study was to identify the determinants
More informationSignificant racial, ethnic, and socioeconomic disparities in
ORIGINAL ARTICLE Race Differences in Initial Presentation, Early Treatment, and 1-year Outcomes of Pediatric Crohn s Disease: Results from the ImproveCareNow Network Jennifer L. Dotson, MD, MPH,*, Michele
More informationPositioning Biologics in Ulcerative Colitis
Positioning Biologics in Ulcerative Colitis Bruce E. Sands, MD, MS Acting Chief, Gastrointestinal Unit Massachusetts General Hospital Associate Professor of Medicine Harvard Medical School Sequential Therapies
More informationMicroscopic Colitis. Darrell S. Pardi, MD Inflammatory Bowel Disease Clinic Mayo Clinic
Microscopic Colitis Darrell S. Pardi, MD Inflammatory Bowel Disease Clinic Mayo Clinic Research Disclosure Astra Zeneca, P&G, Salix* Consulting Salix* *This program is supported by Salix. Neither Mayo
More informationLatest Treatment Updates for Ulcerative Colitis: Evolving Treatment Goals
Latest Treatment Updates for Ulcerative Colitis: Evolving Treatment Goals Stephen Hanauer, MD Professor of Medicine Medical Director, Digestive Disease Center Northwestern Medicine Chicago, Illinois Speaker
More informationCigdem Benlice, Ipek Sapci, T. Bora Cengiz, Luca Stocchi, Michael Valente, Tracy Hull, Scott R. Steele, Emre Gorgun 07/23/2018
Does preoperative oral antibiotic or mechanical bowel preparation increase Clostridium difficile colitis after colon surgery? An assessment from ACS-NSQIP procedure-targeted database Cigdem Benlice, Ipek
More informationMild-moderate Ulcerative Colitis Sequential & Combined treatments need to be tested. Philippe Marteau, Paris, France
Mild-moderate Ulcerative Colitis Sequential & Combined treatments need to be tested Philippe Marteau, Paris, France Sequential vs combined treatments When should one switch? Sequential vs combined treatments
More informationGSK Medicine: Study Number: Title: Rationale: Study Period: Objectives: Indication: Study Investigators/Centers: Research Methods: Data Source
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationMEDICAL POLICY II. III. SUBJECT: MEASUREMENT OF SERUM ANTIBODIES TO INFLIXIMAB, ADALIMUMAB, AND VEDOLIZUMAB
MEDICAL POLICY SUBJECT: MEASUREMENT OF SERUM ANTIBODIES TO INFLIXIMAB, ADALIMUMAB, AND PAGE: 1 OF: 6 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not
More informationGuided by Dr. Michal Amitai Head of Abdominal Imaging Department of Diagnostic Imaging Sheba Medical Center Sackler School of Medicine, Tel Aviv
Guided by Dr. Michal Amitai Head of Abdominal Imaging Department of Diagnostic Imaging Sheba Medical Center Sackler School of Medicine, Tel Aviv University 1 SHARE study My year Collaboration between gastroenterology
More information13-year mortality trends among hospitalized patients with inflammatory bowel disease
Sewell and Yee BMC Gastroenterology 212, 12:79 RESEARCH ARTICLE Open Access 13-year mortality trends among hospitalized patients with inflammatory bowel disease Justin L Sewell * and Hal F Yee Jr Abstract
More informationIBD in teenagers Biological and Transition
IBD in teenagers Biological and Transition Dr Warren Hyer Consultant Paediatric Gastroenterologist St Mark s Hospital Chelsea and Westminster Hospital Conflict of Interest None to declare Fee for presentation
More informationIleal Pouch Anal Anastomosis: The Preferred Method of Reconstruction after Proctocolectomy in Children
Ileal Pouch Anal Anastomosis: The Preferred Method of Reconstruction after Proctocolectomy in Children Stephanie Jones, D.O. Surgical Fellow March 21, 2011 Ulcerative Colitis Spectrum of inflammatory bowel
More informationInflammatory bowel disease (IBD) Overview of the Paediatric investigation plans. Presented by: Richard Veselý. An agency of the European Union
Inflammatory bowel disease (IBD) Overview of the Paediatric investigation plans Presented by: Richard Veselý An agency of the European Union Adalimumab - Crohn s disease Indication: Treatment of severe,
More informationEpidemiology / Morbidity
Perianal Crohn s Disease: Current Treatment Approach David A Schwartz, MD Director, Inflammatory Bowel Disease Center Vanderbilt University Medical Center Epidemiology / Morbidity Hellers et al, Gut 1980
More informationProtocol for the management of acute severe ulcerative colitis in children
Protocol for the management of acute severe ulcerative colitis in children Introduction: Paediatric UC is severe and more extensive than adult onset UC with 6-8% presenting as pancolitis (1,2) Within five
More informationOutline. Biologic Drugs in Inflammatory Bowel Disease Dr. Jason Etzel MD The Vancouver Clinic. Biologic Drugs. Biologic Drugs. Biologic Drugs Anti-TNF
Outline Biologic Drugs in Inflammatory Bowel Disease Dr. Jason Etzel MD The Vancouver Clinic Types of biologic drugs How do they work? How effective are they? Safety/Toxicity concerns with biologics Biologic
More informationLaurie S. Conklin, M.D. Inflammatory Bowel Disease Program Children s National Medical Center
Laurie S. Conklin, M.D. Inflammatory Bowel Disease Program Children s National Medical Center CROHN S DISEASE Patchy inflammation Mouth to anus involvement Full-thickness inflammation Variable involvement
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 1041-8 Program Prior Authorization/Notification Medication Humira (adalimumab) P&T Approval Date 1/2007, 6/2008, 4/2009, 6/2009,
More informationMEDICAL POLICY SUBJECT: GENOTYPING OR PHENOTYPING FOR THIOPURINE METHYLTRANSFERASE (TPMT) FOR PATIENTS TREATED WITH AZATHIOPRINE (6-MP)
MEDICAL POLICY SUBJECT: GENOTYPING OR PHENOTYPING PAGE: 1 OF: 5 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial product (including
More informationIBD 101. Ronen Stein, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition
IBD 101 Ronen Stein, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition Objectives Identify factors involved in the development of inflammatory bowel
More informationNutritional Requirements for Inflammatory Bowel Disease. Dale Lee, MD, MSCE Assistant Professor of Pediatrics University of Washington
Nutritional Requirements for Inflammatory Bowel Disease Dale Lee, MD, MSCE Assistant Professor of Pediatrics University of Washington No disclosures Objectives 1) Review the biological mechanisms disturbed
More informationPediatric Inflammatory Bowel Disease in Less Than 30 Minutes
Pediatric Inflammatory Bowel Disease in Less Than 30 Minutes Shervin Rabizadeh, M.D., M.B.A. Director, Pediatric Gastroenterology and Pediatric Inflammatory Bowel Disease Program Cedars-Sinai Medical Center
More informationEuropean evidence-based consensus on the use of imaging techniques in inflammatory bowel disease diagnosis and management
European evidence-based consensus on the use of imaging techniques in inflammatory bowel disease diagnosis and management J. Martin-Comin Hospital U. Bellvitge Hospitalet de Llobregat Spain THE EUROPEAN
More information11/13/11. Biologics for CD and CUC: The Impact on Surgical Outcomes. Principles of Successful Intestinal Surgery
Biologics for CD and CUC: The Impact on Surgical Outcomes Robert R. Cima, M.D., M.A. Associate Professor of Surgery Division of Colon and Rectal Surgery Overview Antibody based medications (biologics)
More informationFrequency of Diagnosis of Colorectal Cancer with Double Contrast Barium Enema
Bahrain Medical Bulletin, Vol.24, No.3, September 2002 Frequency of Diagnosis of Colorectal Cancer with Double Contrast Barium Enema Najeeb S Jamsheer, MD, FRCR* Neelam. Malik, MD, MNAMS** Objective: To
More informationAdverse Events From Biologic Agents in IBD
Adverse Events From Biologic Agents in IBD David A. Schwartz, MD, FACG Director, Inflammatory Bowel Disease Center Professor of Medicine Vanderbilt University Medical Center Case Page 1 of 24 28 yo with
More informationThe York Faecal Calprotectin Care Pathway for use in primary care. James Turvill
The York Faecal Calprotectin Care Pathway for use in primary care James Turvill NICE guidance: dg11 Faecal calprotectin (FC) testing as an option in adults with recent onset of lower gastrointestinal symptoms
More informationAnne Griffiths MD, FRCPC. SickKids Hospital, University of Toronto. Buenos Aires, August 16, 2014
Management and Medical Therapies for Crohn disease: strategies to enhance mucosal healing Anne Griffiths MD, FRCPC SickKids Hospital, University of Toronto Buenos Aires, August 16, 2014 New onset Crohn
More informationTREATMENT OF INPATIENTS WITH ACUTE SEVERE ULCERATIVE COLITIS
TREATMENT OF INPATIENTS WITH ACUTE SEVERE ULCERATIVE COLITIS Target Audience: Physicians, Physician Assistants, Nurse Practitioners and Nurses impacted by the protocol. Scope/Patient Population: All adult
More informationOf Treatment For Inflammatory Bowel Diseases
Balancing The Risks And Benefits Of Treatment For Inflammatory Bowel Diseases Corey A. Siegel, MD Assistant Professor of Medicine Dartmouth Medical School Director, Inflammatory Bowel Diseases Center Dartmouth-Hitchcock
More information